News

Company   ImmuPharma PLC
TIDM         IMM
Headline     Interim Results
Released    07:00 29-Sep-2009
Number     8000Z07

FOR IMMEDIATE RELEASE

London, 29 September 2009

Interim Results for the six months ended 30 June 2009
ImmuPharma plc reports revenue of £21.6m

ImmuPharma plc (LSE:IMM), the specialist discovery and development pharmaceutical company is pleased to announce its interim results for the six months ended 30 June 2009.

INTERIM HIGHLIGHTS

Revenue reported of £21.6m for the period following the receipt of $30m from Cephalon, Inc. as a license payment for LupuzorTM in February
Basic and diluted earnings per share were 15.05p and 13.69p respectively (31 December 2008: 6.23p and 5.72p respectively)
Strong cash position of £27m (as at 30 June 2009)
Interim analysis of Phase IIb data for LupuzorTM showed statistically significant superiority over placebo
Cephalon, Inc. exercised their right to license LupuzorTM with a $30m license payment with the potential for various future cash milestone payments totalling up to $500m as well as royalties on any future sales. Cephalon, Inc. will also assume responsibility for all future costs and activities for LupuzorTM.
Received 'Breakthrough of the Year 2009' European Mediscience Award

Post Review Period

A total of 12.5 million ordinary shares (16.1% of the issued share capital) was acquired at a price of 86 pence per share to institutional investors on 23 July 2009, including M&G Investments

Commenting on the progress to date and the outlook for ImmuPharma, Dimitri Dimitriou, Chief Executive Officer, said: "The first half of 2009 has been a truly exciting time in the history of ImmuPharma. The promising interim analysis for LupuzorTM's Phase IIb data and its subsequent licensing to Cephalon, Inc. has been a big step forward in ImmuPharma's development. We look forward to building on this success during the rest of 2009 and in the coming years."

For further information please contact:

ImmuPharma PLC +44 20 7152 4080

Dimitri Dimitriou, Chief Executive Officer
Richard Warr, Chairman
Tracy Weimar, Vice President, Operations

Buchanan Communications +44 20 7466 5000

Lisa Baderoon

Panmure Gordon & Co 44 151 243 0963

Andrew Burnett

Full report :


Home About ImmuPharma Lead compounds Discovery pipeline Management team News For Investors Contact us	News Company ImmuPharma PLC TIDM IMM Headline Interim Results Released 07:00 29-Sep-2009 Number 8000Z07 FOR IMMEDIATE RELEASE London, 29 September 2009 Interim Results for the six months ended 30 June 2009 ImmuPharma plc reports revenue of £21.6m ImmuPharma plc (LSE:IMM), the specialist discovery and development pharmaceutical company is pleased to announce its interim results for the six months ended 30 June 2009. INTERIM HIGHLIGHTS Revenue reported of £21.6m for the period following the receipt of $30m from Cephalon, Inc. as a license payment for LupuzorTM in February Basic and diluted earnings per share were 15.05p and 13.69p respectively (31 December 2008: 6.23p and 5.72p respectively) Strong cash position of £27m (as at 30 June 2009) Interim analysis of Phase IIb data for LupuzorTM showed statistically significant superiority over placebo Cephalon, Inc. exercised their right to license LupuzorTM with a $30m license payment with the potential for various future cash milestone payments totalling up to $500m as well as royalties on any future sales. Cephalon, Inc. will also assume responsibility for all future costs and activities for LupuzorTM. Received 'Breakthrough of the Year 2009' European Mediscience Award Post Review Period A total of 12.5 million ordinary shares (16.1% of the issued share capital) was acquired at a price of 86 pence per share to institutional investors on 23 July 2009, including M&G Investments Commenting on the progress to date and the outlook for ImmuPharma, Dimitri Dimitriou, Chief Executive Officer, said: "The first half of 2009 has been a truly exciting time in the history of ImmuPharma. The promising interim analysis for LupuzorTM's Phase IIb data and its subsequent licensing to Cephalon, Inc. has been a big step forward in ImmuPharma's development. We look forward to building on this success during the rest of 2009 and in the coming years." For further information please contact: ImmuPharma PLC +44 20 7152 4080 Dimitri Dimitriou, Chief Executive Officer Richard Warr, Chairman Tracy Weimar, Vice President, Operations Buchanan Communications +44 20 7466 5000 Lisa Baderoon Panmure Gordon & Co 44 151 243 0963 Andrew Burnett Full report : ©2009 London Stock Exchange plc. All rights reserved